NASDAQ
No price data available for this timeframe.
Amedisys, Inc. (AMED) has a consensus Hold rating from 28 analysts with an average price target of $143.38, representing +42.0% upside from the current price of $100.99.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Mar 25, 2024 | Frank Morgan | RBC Capital | $100.00 | $92.16 | +8.51% |
| Jul 6, 2023 | Brian Tanquilut | Jefferies | $90.80 | $91.28 | -0.53% |
| Jan 5, 2023 | Unknown | Leerink Partners | $85.00 | $86.00 | -1.16% |
| Nov 11, 2022 | Unknown | Stephens | $106.00 | $91.78 |
Apr 16, 2025 | Maintained | RBC Capital | Outperform | Outperform |
Mar 4, 2025 | Maintained | Stephens & Co. | Equal Weight | Equal Weight |
Feb 12, 2025 | Maintained | Stephens & Co. | Equal Weight | Equal Weight |
Jul 31, 2024 | Downgrade | Deutsche Bank | Buy | Hold |
Jul 25, 2024 | Maintained | Cantor Fitzgerald | Neutral | Neutral |
| Jul 26, 2022 | David MacDonald | Truist Financial | $150.00 | $128.18 | +17.02% |